HomeCompareFPHAF vs BTI

FPHAF vs BTI: Dividend Comparison 2026

FPHAF yields 60.61% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FPHAF wins by $633.4K in total portfolio value
10 years
FPHAF
FPHAF
● Live price
60.61%
Share price
$3.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$671.2K
Annual income
$158,074.64
Full FPHAF calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — FPHAF vs BTI

📍 FPHAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFPHAFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FPHAF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FPHAF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FPHAF
Annual income on $10K today (after 15% tax)
$5,151.52/yr
After 10yr DRIP, annual income (after tax)
$134,363.44/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, FPHAF beats the other by $131,981.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FPHAF + BTI for your $10,000?

FPHAF: 50%BTI: 50%
100% BTI50/50100% FPHAF
Portfolio after 10yr
$354.5K
Annual income
$80,438.46/yr
Blended yield
22.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

FPHAF
No analyst data
Altman Z
-17.1
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FPHAF buys
0
BTI buys
0
No recent congressional trades found for FPHAF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFPHAFBTI
Forward yield60.61%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$671.2K$37.8K
Annual income after 10y$158,074.64$2,802.29
Total dividends collected$557.6K$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: FPHAF vs BTI ($10,000, DRIP)

YearFPHAF PortfolioFPHAF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$16,761$6,060.61$11,301$601.08+$5.5KFPHAF
2$27,427$9,493.40$12,799$706.58+$14.6KFPHAF
3$43,866$14,518.80$14,527$832.38+$29.3KFPHAF
4$68,638$21,701.63$16,527$982.75+$52.1KFPHAF
5$105,179$31,735.61$18,846$1,162.95+$86.3KFPHAF
6$157,990$45,448.98$21,545$1,379.49+$136.4KFPHAF
7$232,853$63,803.27$24,694$1,640.41+$208.2KFPHAF
8$337,036$87,884.16$28,378$1,955.69+$308.7KFPHAF
9$479,513$118,883.79$32,702$2,337.79+$446.8KFPHAF
10$671,153$158,074.64$37,794$2,802.29+$633.4KFPHAF

FPHAF vs BTI: Complete Analysis 2026

FPHAFStock

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Full FPHAF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this FPHAF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FPHAF vs SCHDFPHAF vs JEPIFPHAF vs OFPHAF vs KOFPHAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.